 |
| |
 |
| |
 |
| |
 |
| |
 |
_____________________________________________________________________________________________________________________
© 2005-9 All Rights Reserved. NOD Pharmaceuticals, Inc.
About Us
 |  |  |
Dr. Lee is a seasoned entrepreneur and has over 12 year biotechnology industry experience since the
post-doctoral training at Parke-Davis/University of Michigan joint program. Before co-founding
NOD Pharmaceuticals, Inc., Dr. Lee has founded BioAge Pharmaceuticals, Inc. and formed extensive
collaboration network, particularly in China. Dr. Lee has developed several key technologies,
including NOD technology, and successfully completed 4 technology license deals in China. Dr. Lee
is responsible for the operation of NOD Pharmaceuticals, Inc. as well as its subsidiary, Biolaxy.
post-doctoral training at Parke-Davis/University of Michigan joint program. Before co-founding
NOD Pharmaceuticals, Inc., Dr. Lee has founded BioAge Pharmaceuticals, Inc. and formed extensive
collaboration network, particularly in China. Dr. Lee has developed several key technologies,
including NOD technology, and successfully completed 4 technology license deals in China. Dr. Lee
is responsible for the operation of NOD Pharmaceuticals, Inc. as well as its subsidiary, Biolaxy.
| William Lee, Ph.D., CEO, NOD Pharmaceuticals, Inc. |
| Zhi Yang, Ph.D., Managing Partner, BioVeda China |
| Damien Lim, General Partner, BioVeda Capital |
Dr. Zhi Yang is co-founder and Managing Partner of BioVeda China. He has over two decades of
experience in biotechnology, having held senior scientific and management positions in a variety of
biotech and pharmaceutical companies, including Sinogen, Incyte Pharmaceuticals, Prolinx, Sandoz
Pharmaceuticals, and Systemix. During his industry years, he was interim CEO, VP Business
Development, VP of R&D, Director of Molecular Biology, Group Leader and Senior/Principal
Scientist. As an entrepreneur, he co-founded BioChain Institute, Genex Biosciences and Crimson
Pharmaceuticals. He is also the principal inventor of more than 10 U.S. and international patents.
Prior to joining industry, Zhi was a senior associate fellow and faculty member at Rockefeller
University. He holds a M.A., Ph.D. in Biochemistry and Molecular Biology from Harvard
University, where his thesis advisors were Dr. Walter Gilbert, a Nobel laureate, and Dr. Jack
Strominger, a world-renowned immunologist. Zhi was among the first group of CUSBEA students
from China to study in the U.S. He obtained his B.S. in Virology from Wuhan University.
experience in biotechnology, having held senior scientific and management positions in a variety of
biotech and pharmaceutical companies, including Sinogen, Incyte Pharmaceuticals, Prolinx, Sandoz
Pharmaceuticals, and Systemix. During his industry years, he was interim CEO, VP Business
Development, VP of R&D, Director of Molecular Biology, Group Leader and Senior/Principal
Scientist. As an entrepreneur, he co-founded BioChain Institute, Genex Biosciences and Crimson
Pharmaceuticals. He is also the principal inventor of more than 10 U.S. and international patents.
Prior to joining industry, Zhi was a senior associate fellow and faculty member at Rockefeller
University. He holds a M.A., Ph.D. in Biochemistry and Molecular Biology from Harvard
University, where his thesis advisors were Dr. Walter Gilbert, a Nobel laureate, and Dr. Jack
Strominger, a world-renowned immunologist. Zhi was among the first group of CUSBEA students
from China to study in the U.S. He obtained his B.S. in Virology from Wuhan University.
private equity and investment banking experience. He was previously Director of Investments with
PrimePartners, a boutique private equity firm. Prior to that, he was Executive Director of Vickers
Ballas Asset Management and concurrently Senior Vice President of Vickers Ballas Holdings (now
part of DBS Bank) where he was involved in private equity investments and strategic acquisitions.
Prior to Vickers, he was Associate Director, Corporate Finance with Morgan Grenfell Asia (now
part of Deutsche Bank), where he managed IPOs, debt and equity financing, and corporate advisory
transactions. Mr. Lim started his career as a financial journalist with the Straits Times. He received
his BBA from the University of Houston.
PrimePartners, a boutique private equity firm. Prior to that, he was Executive Director of Vickers
Ballas Asset Management and concurrently Senior Vice President of Vickers Ballas Holdings (now
part of DBS Bank) where he was involved in private equity investments and strategic acquisitions.
Prior to Vickers, he was Associate Director, Corporate Finance with Morgan Grenfell Asia (now
part of Deutsche Bank), where he managed IPOs, debt and equity financing, and corporate advisory
transactions. Mr. Lim started his career as a financial journalist with the Straits Times. He received
his BBA from the University of Houston.
NOD Pharmaceuticals is a privately held innovative drug delivery company. The Company is
funded by professional venture firms, including BioVeda China and CRCI.
The Board of Directors include the following individuals:
funded by professional venture firms, including BioVeda China and CRCI.
The Board of Directors include the following individuals:
| Andrew Lo, Ph.D., J.D., Director, CRCI Capital |
Dr. Lo is a director at China Renaissance Capital Investment and has extensive experience in
managing portfolio companies, merge and acquisitions.
managing portfolio companies, merge and acquisitions.
NOD
Pharmaceuticals, Inc.
| Innovation Delivered |
| | |